Private company

INFINITY PHARMACEUTICALS, INC.

American pharmaceutical preparations company based in Cambridge.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersCambridge, United States
Incorporated inDE²
Business address1100 Massachusetts Avenue, Floor 4, Cambridge, Ma 02138²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1729.4%Operating margin³

-1711.1%Net margin³

39.6%Revenue growth, 2022³

-$42.4MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development100¢$32.4M

Out of $2.6M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷³$2.6M in 2022−57% since 2017

Operating income⁸⁴⁵⁶⁷³-$44.8M in 2022+45% since 2016

Net income⁸⁴⁵⁶⁷³-$44.4M in 2022+47% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue		$6.0M⁴	$22.1M⁵	$3.0M⁶	$1.7M⁷	$1.9M³	$2.6M³
Research and development	$119.6M⁸	$20.8M⁴	$19.8M⁵	$27.1M⁶	$26.8M⁷	$31.6M³	$32.4M³
Operating income	-$30.9M⁸	-$36.4M⁴	-$11.9M⁵	-$45.7M⁶	-$38.5M⁷	-$45.1M³	-$44.8M³
Interest	$1.2M⁸	$1.0M⁴	$93.0K⁵	$2.6M⁵
Income tax	$0⁸	-$720.0K⁴	$0⁵	-$54.0K⁶	$0⁷	$0³	$0³
Net income	-$30.1M⁸	-$41.8M⁴	-$11.3M⁵	-$47.1M⁶	-$40.5M⁷	-$45.3M³	-$44.4M³
Earnings per share					-$0.68⁷	-$0.53³	-$0.50³
Earnings per share (diluted)					-$0.68⁷	-$0.53³	-$0.50³

Total assets⁸⁴⁵⁶⁷³$42.2M in 2022−66% since 2016

Total liabilities⁸⁴⁵⁶⁷³$61.2M in 2022+42% since 2016

Shareholders’ equity⁴⁵⁶⁷³-$19.1M in 2022

Cash⁴⁵⁶⁷³$38.3M in 2022−48% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$74.1M⁴	$34.6M⁴	$48.6M⁵	$22.3M⁶	$28.6M⁷	$80.7M³	$38.3M³
Current assets	$101.7M⁸	$58.4M⁴	$59.8M⁵	$44.6M⁶	$36.0M⁷	$82.3M³	$40.3M³
Total assets	$125.7M⁸	$59.4M⁴	$60.2M⁵	$49.0M⁶	$39.3M⁷	$84.8M³	$42.2M³
Current liabilities	$23.9M⁸	$11.6M⁴	$7.7M⁵	$9.7M⁶	$11.0M⁷	$13.3M³	$13.6M³
Total liabilities	$43.2M⁸	$11.6M⁴	$7.8M⁵	$41.3M⁶	$62.3M⁷	$63.2M³	$61.2M³
Shareholders’ equity	$82.5M⁴	$47.7M⁵	$52.5M⁶	$7.7M⁷	-$23.0M³	$21.6M³	-$19.1M³
Shares outstanding	50.4M shares⁸	50.8M shares⁴	56.9M shares⁵	57.1M shares⁶	64.3M shares⁷	89.2M shares³	89.4M shares³

Cash from operations⁴⁵⁶⁷³-$42.4M in 2022+16% since 2017

Capital spending⁸⁴⁵⁶⁷³$17.0K in 2022−97% since 2016

Free cash flow⁴⁵⁶⁷³-$42.4M in 2022+15% since 2017

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations		-$36.7M⁴	-$4.7M⁵	-$41.5M⁶	-$35.7M⁷	-$40.6M³	-$42.4M³
Capital spending	$661.0K⁸	$43.0K⁴	$0⁵	$2.3M⁶	$43.0K⁷	$11.0K³	$17.0K³
Free cash flow		-$36.8M	-$4.7M	-$43.9M	-$35.8M	-$40.6M	-$42.4M

Compare INFINITY PHARMACEUTICALS, INC. with another company

Leadership

Who has led INFINITY PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Steven H. Holtzman2007–2010

President

Chief financial officer

2010201520202025

Chief executive officerAdelene Q. Perkins Jan 7, 2010 to Jan 12, 2022¹¹
Chief executive officerSteven H. Holtzman Sep 13, 2006 to Jan 7, 2009¹²
ChairSteven H. Holtzman Sep 18, 2007 to Dec 13, 2010¹³
PresidentLawrence E. Bloch Jan 9, 2017 to Jan 12, 2022¹⁴
PresidentAdelene Q. Perkins Jan 16, 2015 to Nov 2, 2016¹⁵
PresidentSteven H. Holtzman Dec 14, 2007 to Aug 29, 2008¹⁶
PresidentJulian Adams Sep 13, 2006 to Nov 2, 2016¹⁷
Chief financial officerLawrence E. Bloch Jul 25, 2012 to Nov 2, 2016¹⁸
Chief financial officerAdelene Q. Perkins Sep 13, 2006 to Jan 29, 2007¹⁹

Board members and other officers (45)

Chief Scientific OfficerStephane Peluso Aug 3, 2021 to Aug 4, 2022²⁰
Chief Medical OfficerRobert Ilaria Jr. Sep 3, 2021 to Jan 12, 2022²¹
Chief Business OfficerSeth A. Tasker Jan 13, 2020 to Jan 12, 2022²²
Chief Medical OfficerSamuel Agresta Aug 7, 2018 to Jan 7, 2019²³
Chief Scientific OfficerJeffery Kutok Feb 14, 2017 to Jan 13, 2020²⁴
Chief Commercial OfficerSujay Kango Apr 1, 2015 to Dec 14, 2016²⁵
Chief Medical OfficerDavid Roth Feb 7, 2014 to Jan 16, 2015²⁶
VP, Business & Corporate DevJoshua Hamermesh May 19, 2011 to Jan 8, 2013²⁷
VP,Cor. Affairs & Gnrl CounselGerald E. Quirk Jan 7, 2010 to Jan 9, 2012²⁸
VP, Cor. & Product DevelopmentJeffrey K. Tong Jan 7, 2010 to Jan 7, 2010²⁹
Chief Scientific OfficerVito J. Palombella May 26, 2010 to Jun 16, 2015³⁰
Vice President, MarketingWinselow S. Tucker Jr. May 26, 2010 to Jan 8, 2013³¹
Chief Medical OfficerPedro Santabarbara Dec 13, 2010 to Jan 14, 2014³²
Chief Scientific OfficerJulian Adams Dec 8, 2008 to Dec 8, 2008³³
EVP and Chief Business OfficerAdelene Q. Perkins May 7, 2007 to Jan 9, 2012³⁴
Vice PresidentRichard Neale Apr 4, 2006 to Aug 16, 2006³⁵
Assistant TreasurerChristopher M. Lindblom Oct 27, 2006 to May 4, 2016³⁶
Board memberSujay Kango Mar 31, 2022 to Mar 31, 2022³⁷
Board memberBrian Schwartz Sep 10, 2021 to Jun 16, 2022³⁸
Board memberSamuel Agresta Oct 16, 2019 to Jun 16, 2022³⁹
Board memberDavid W. Beier Apr 2, 2018 to Jun 16, 2022⁴⁰
Board memberMichael Kauffman Apr 6, 2017 to Jun 14, 2019⁴¹
Board memberMark N. Lampert Dec 2, 2016 to Jan 5, 2017⁴²
Board memberJeffrey Berkowitz Mar 10, 2014 to Jun 14, 2019⁴³
Board memberJose Baselga Mar 10, 2014 to Jan 9, 2017⁴⁴
Board memberGwen A. Fyfe Mar 12, 2012 to Jun 16, 2015⁴⁵
Board memberNorman C. Selby Mar 12, 2012 to Jun 16, 2022⁴⁶
Board memberAdelene Q. Perkins Jan 7, 2010 to Sep 12, 2023¹¹
Board memberIan F. Smith May 23, 2008 to Jun 14, 2018⁴⁷
Board memberMartin Babler May 23, 2008 to Jun 13, 2013⁴⁸
Board memberHarry F. Hixson Jr. Feb 14, 2006 to Jun 19, 2009⁴⁹
Board memberAlan Lewis May 12, 2006 to May 12, 2006⁵⁰
Board memberColin Dollery May 12, 2006 to May 12, 2006⁵¹
Board memberHerm Rosenman May 12, 2006 to Sep 14, 2007⁵²
Board memberArnold J. Levine Sep 13, 2006 to May 19, 2011⁵³
Board memberEric S. Lander Sep 13, 2006 to Jun 21, 2016⁵⁴
Board memberFranklin Moss Sep 13, 2006 to May 27, 2010⁵⁵
Board memberJames B. Tananbaum Sep 13, 2006 to May 19, 2011⁵⁶
Board memberMichael C. Venuti Sep 13, 2006 to Jun 18, 2020⁵⁷
Board memberSteven H. Holtzman Sep 13, 2006 to Jun 4, 2012¹²
Board memberVicki L. Sato Sep 13, 2006 to May 23, 2008⁵⁸
Board memberAnthony B. Evnin Sep 14, 2006 to Jun 16, 2022⁵⁹
General counselSeth A. Tasker Jul 29, 2016 to Jan 7, 2019⁶⁰
General counselWinston K.c. Lam Apr 15, 2015 to Apr 15, 2015⁶¹
General counselWilliam C. Bertrand Jr. Oct 21, 2015 to Oct 21, 2015⁶²

Former names

DISCOVERY PARTNERS INTERNATIONAL INCJun 23, 2000 to Sep 11, 2006²

Timeline

Jan 7, 2010New chief executive Adelene Q. Perkins becomes CEO¹¹
Sep 13, 2006New chief executive Steven H. Holtzman becomes CEO¹²

Filings

77 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 24 major events, 15 insider forms, 9 large holders, 21 other. The latest 20:

Nov 20, 202325-NSE EDGAR
Sep 29, 20238-K EDGAR
Sep 13, 20238-K EDGAR
Sep 12, 20234 FORM 4 SUBMISSION EDGAR
Sep 11, 20238-K EDGAR
Sep 1, 20238-K EDGAR
Aug 10, 202310-Q EDGAR
Jul 25, 20238-K EDGAR
Jul 24, 20238-K EDGAR
Jul 14, 20238-K EDGAR
Jul 10, 2023DEFA14A EDGAR
Jul 5, 2023DEFA14A EDGAR
Jul 3, 2023425 EDGAR
Jul 3, 20238-K EDGAR
Jul 3, 2023DEFA14A EDGAR
Jun 30, 20238-K EDGAR
Jun 29, 2023DEFA14A EDGAR
Jun 27, 2023DEFA14A EDGAR
Jun 21, 2023DEFA14A EDGAR
Jun 20, 2023DEFA14A EDGAR

The 77 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 9 such filings since October 2021:

Feb 14, 2023SC 13G/A
Feb 9, 2023SC 13G/A
Jul 8, 2022SC 13G
Feb 14, 2022SC 13G
Feb 14, 2022SC 13G/A
Feb 14, 2022SC 13G/A
Feb 10, 2022SC 13G
Feb 4, 2022SC 13G
Jan 18, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARINFINITY PHARMACEUTICALS, INC. filings on SEC EDGAR
2
SEC EDGARINFINITY PHARMACEUTICALS, INC. filings on SEC EDGAR
3
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2022
4
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2017
5
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2018
6
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2019
7
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2020
8
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-K for fiscal 2016
9
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-Q for fiscal 2023
10
SEC EDGARINFINITY PHARMACEUTICALS, INC. 10-Q for fiscal 2023
11
SEC EDGARAdelene Q. Perkins, Chief executive officer
12
SEC EDGARSteven H. Holtzman, Chief executive officer
13
SEC EDGARSteven H. Holtzman, Chair
14
SEC EDGARLawrence E. Bloch, President
15
SEC EDGARAdelene Q. Perkins, President
16
SEC EDGARSteven H. Holtzman, President
17
SEC EDGARJulian Adams, President
18
SEC EDGARLawrence E. Bloch, Chief financial officer
19
SEC EDGARAdelene Q. Perkins, Chief financial officer
20
SEC EDGARStephane Peluso, Chief Scientific Officer
21
SEC EDGARRobert Ilaria Jr., Chief Medical Officer
22
SEC EDGARSeth A. Tasker, Chief Business Officer
23
SEC EDGARSamuel Agresta, Chief Medical Officer
24
SEC EDGARJeffery Kutok, Chief Scientific Officer
25
SEC EDGARSujay Kango, Chief Commercial Officer
26
SEC EDGARDavid Roth, Chief Medical Officer
27
SEC EDGARJoshua Hamermesh, VP, Business & Corporate Dev
28
SEC EDGARGerald E. Quirk, VP,Cor. Affairs & Gnrl Counsel
29
SEC EDGARJeffrey K. Tong, VP, Cor. & Product Development
30
SEC EDGARVito J. Palombella, Chief Scientific Officer
31
SEC EDGARWinselow S. Tucker Jr., Vice President, Marketing
32
SEC EDGARPedro Santabarbara, Chief Medical Officer
33
SEC EDGARJulian Adams, Chief Scientific Officer
34
SEC EDGARAdelene Q. Perkins, EVP and Chief Business Officer
35
SEC EDGARRichard Neale, Vice President
36
SEC EDGARChristopher M. Lindblom, Assistant Treasurer
37
SEC EDGARSujay Kango, Board member
38
SEC EDGARBrian Schwartz, Board member
39
SEC EDGARSamuel Agresta, Board member
40
SEC EDGARDavid W. Beier, Board member
41
SEC EDGARMichael Kauffman, Board member
42
SEC EDGARMark N. Lampert, Board member
43
SEC EDGARJeffrey Berkowitz, Board member
44
SEC EDGARJose Baselga, Board member
45
SEC EDGARGwen A. Fyfe, Board member
46
SEC EDGARNorman C. Selby, Board member
47
SEC EDGARIan F. Smith, Board member
48
SEC EDGARMartin Babler, Board member
49
SEC EDGARHarry F. Hixson Jr., Board member
50
SEC EDGARAlan Lewis, Board member
51
SEC EDGARColin Dollery, Board member
52
SEC EDGARHerm Rosenman, Board member
53
SEC EDGARArnold J. Levine, Board member
54
SEC EDGAREric S. Lander, Board member
55
SEC EDGARFranklin Moss, Board member
56
SEC EDGARJames B. Tananbaum, Board member
57
SEC EDGARMichael C. Venuti, Board member
58
SEC EDGARVicki L. Sato, Board member
59
SEC EDGARAnthony B. Evnin, Board member
60
SEC EDGARSeth A. Tasker, General counsel
61
SEC EDGARWinston K.c. Lam, General counsel
62
SEC EDGARWilliam C. Bertrand Jr., General counsel